Bio-Rad Announces Innovative Test to Aid in the Diagnosis of Lyme Disease with the FDA Clearance of the BioPlex 2200 Lyme Total Assay

HERCULES, Calif.–(BUSINESS WIRE)–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life
science research and clinical diagnostic products, today announced that
it has received U.S. Food and Drug Administration (FDA) clearance for
its BioPlex 2200 Lyme Total Assay, an innovative multiplex test method
to aid in the diagnosis of Lyme disease.

Lyme disease is the most common tick-borne illness in the United States.
Many signs and symptoms of the disease are similar to other conditions
so diagnosis can be challenging; however, individuals immediately
treated for the disease usually recover rapidly and completely. The
BioPlex 2200 Lyme Total Assay can simultaneously detect multiple
targets, providing laboratories valuable information in the early stages
of Lyme disease so patients are able to receive treatment as quickly as
possible.

“The addition of the BioPlex 2200 Lyme Total assay broadens our BioPlex
2200 System infectious disease menu, offering laboratories the ability
to detect Lyme disease at an early stage and thus fulfilling an
important medical need in the management of Lyme disease,” said John
Hertia, Bio-Rad President, Clinical Diagnostics Group.

The release of the BioPlex 2200 Lyme Total assay is the latest offering
in Bio-Rad’s infectious disease menu for the BioPlex 2200 System, an
automated multiplex technology platform. The BioPlex 2200 System
provides clinical laboratories the capability to rapidly process or
“multiplex” multiple individual tests that are traditionally processed
separately, conserving patient sample volume and simplifying workflow.

Bio-Plex and Bio-Rad are trademarks of Bio-Rad Laboratories, Inc. in
certain jurisdictions

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in
developing, manufacturing, and marketing a broad range of innovative
products for the life science research and clinical diagnostic markets.
With a focus on quality and customer service for over 65 years, our
products advance the discovery process and improve healthcare. Our
customers are university and research institutions, hospitals, public
health and commercial laboratories, biotechnology, pharmaceutical, as
well as applied laboratories that include food safety and environmental
quality. Founded in 1952, Bio-Rad is based in Hercules, California, and
has a global network of operations with more than 8,000 employees
worldwide. Bio-Rad had revenues exceeding $2.2 billion in 2018. For more
information, please visit www.bio-rad.com.

This release may be deemed to contain certain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements include, without
limitation, statements we make regarding plans to introduce new products
and our expectations regarding our products. Forward-looking statements
generally can be identified by the use of forward-looking terminology
such as “will”, “believe,” “expect,” “anticipate,” “may,” “plan,”
“intend,” “estimate,” “offers,” or similar expressions or the negative
of those terms or expressions, although not all forward-looking
statements contain these words. Such statements involve risks and
uncertainties, which could cause actual results to vary materially from
those expressed in or indicated by the forward-looking statements. These
risks and uncertainties include our ability to develop and market new or
improved products, our ability to compete effectively, international
legal and regulatory risks, and product quality and liability issues.
For further information regarding our risks and uncertainties, please
refer to the “Risk Factors” and “Management’s Discussion and Analysis of
Financial Condition and Results of Operation” in Bio-Rad’s public
reports filed with the Securities and Exchange Commission, including our
most recent Annual Report on Form 10-K and our Quarterly Reports on Form
10-Q. Bio-Rad cautions you not to place undue reliance on
forward-looking statements, which reflect an analysis only and speak
only as of the date hereof. We disclaim any obligation to update these
forward-looking statements.

Contacts

Bio-Rad Laboratories, Inc.
Tina Cuccia, Corporate Communications
510-724-7000
[email protected]